| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JALZ.2016.01.003 |
| P698 | PubMed publication ID | 26892233 |
| P50 | author | Jonathan D Rohrer | Q42407224 |
| Mark Lythgoe | Q45031555 | ||
| Priya Gami | Q52280413 | ||
| Thibault Gendron | Q56800132 | ||
| Tammaryn Lashley | Q85290690 | ||
| P2093 | author name string | Tamas Revesz | |
| Nick C Fox | |||
| Kerstin Sander | |||
| Jonathan M Schott | |||
| Erik Årstad | |||
| P433 | issue | 11 | |
| P921 | main subject | positron emission tomography | Q208376 |
| Alzheimer's disease | Q11081 | ||
| P304 | page(s) | 1116-1124 | |
| P577 | publication date | 2016-02-15 | |
| P1433 | published in | Alzheimer's and Dementia | Q15750965 |
| P1476 | title | Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias | |
| P478 | volume | 12 |
| Q46616293 | 18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study |
| Q37198563 | 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers |
| Q53396939 | 18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. |
| Q101564229 | 18F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty |
| Q37633577 | AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies |
| Q90198060 | Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development |
| Q37001820 | An autoradiographic evaluation of AV-1451 Tau PET in dementia |
| Q64261095 | Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease |
| Q64106160 | Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue |
| Q64952063 | Biomarkers for tau pathology. |
| Q38979999 | Biomarkers for the Early Detection and Progression of Alzheimer's Disease |
| Q92628969 | Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants |
| Q91555490 | Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease |
| Q47140361 | Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. |
| Q90214060 | Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology |
| Q38640294 | Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau. |
| Q64298179 | Dementia spectrum disorders: lessons learnt from decades with PET research |
| Q58794612 | Disease-related patterns of in vivo pathology in Corticobasal syndrome |
| Q60433904 | Distinct [F]THK5351 binding patterns in primary progressive aphasia variants |
| Q39021126 | Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. |
| Q92402592 | Effect of Off-Target Binding on 18F-Flortaucipir Variability in Healthy Controls Across the Life Span |
| Q64115558 | F-Flortaucipir in TDP-43 associated frontotemporal dementia |
| Q61804682 | F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes |
| Q93083717 | FTD spectrum: Neuroimaging across the FTD spectrum |
| Q47684719 | Flortaucipir tau PET imaging in semantic variant primary progressive aphasia |
| Q46753514 | Head to head comparison of [(18)F] AV-1451 and [(18)F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia. |
| Q90707233 | Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948 |
| Q54965551 | Imaging Aβ and tau in early stage Alzheimer's disease with [18F]AV45 and [18F]AV1451. |
| Q39419877 | Imaging tau pathology in Parkinsonisms |
| Q41591680 | In vivo retention of 18F-AV-1451 in corticobasal syndrome. |
| Q48486327 | Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy |
| Q48011375 | Knowing your enemy: from post-mortem scene reconstruction to real-time monitoring of the spread of tau and amyloid |
| Q55254017 | Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias. |
| Q42672461 | Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case |
| Q64814750 | MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy |
| Q54946040 | Molecular biomarkers of Alzheimer's disease: progress and prospects. |
| Q39346750 | Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias |
| Q46936274 | Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration |
| Q55494083 | Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy. |
| Q90373014 | Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum |
| Q47329627 | New advances in tau imaging in parkinsonism |
| Q90658867 | Parametric methods for [18F]flortaucipir PET |
| Q48389127 | Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies |
| Q47279644 | Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy |
| Q47809826 | Positron emission tomography imaging of tau pathology in progressive supranuclear palsy |
| Q47918679 | Preclinical Evaluation of (18)F-RO6958948, (11)C-RO6931643 and (11)C-RO6924963 as Novel Radiotracers for Imaging Aggregated Tau in AD with Positron Emission Tomography |
| Q40259674 | Quantification of Tau Load Using [(18)F]AV1451 PET. |
| Q39303669 | Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? |
| Q37739881 | Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition |
| Q47926474 | Small-molecule PET Tracers for Imaging Proteinopathies |
| Q34682521 | Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers |
| Q90407269 | Tau Imaging in Parkinsonism: What Have We Learned So Far? |
| Q91011085 | Tau PET imaging in neurodegenerative tauopathies-still a challenge |
| Q47985518 | Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease. |
| Q34680852 | Tau PET imaging: present and future directions |
| Q46634925 | Tau PET: the next frontier in molecular imaging of dementia |
| Q39365272 | Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases |
| Q49295547 | Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms. |
| Q64071535 | Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain |
| Q42334587 | Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy |
| Q37515094 | Tau prions from Alzheimer's disease and chronic traumatic encephalopathy patients propagate in cultured cells |
| Q49900567 | Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech |
| Q38633337 | Tau-imaging in neurodegeneration |
| Q56594907 | The development and validation of tau PET tracers: current status and future directions |
| Q42701971 | The emerging role of PET imaging in dementia. |
| Q48261458 | [18 F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease |
| Q41350096 | [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy |
| Q87934114 | [18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation |
| Q47547648 | [18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. |
| Q37577889 | [18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation. |
| Q47252490 | [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. |
| Q49937027 | [18F]AV-1451 tau-PET and primary progressive aphasia |
| Q48505309 | [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration |
| Q47694602 | [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging |
| Q57822208 | [F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion |
Search more.